Xiaohong Shu

2.2k citations
63 papers · 1.8k indexed · h-index 26
Topics
Sirtuins and Resveratrol in Medicine (12 papers)Cancer Mechanisms and Therapy (8 papers)Receptor Mechanisms and Signaling (5 papers)

In The Last Decade

Xiaohong Shu

61 papers receiving 1.7k citations

Peers

Xiaohong Shu
Comparison fields: 5 of 113
  • Molecular Biology 934
  • Oncology 315
  • Cancer Research 296
  • Geriatrics and Gerontology 290
  • Organic Chemistry 189
Replace Xinqun Li with:
Xinqun Li United States
Tohru Yamamori Japan
Xuqi Li China
Gyesoon Yoon South Korea
Shikun He United States
Wanxing Duan China
Anait S. Levenson United States
Rebecca S. Keller United States
Xiaohong Shu relative to Xinqun Li United States Xinqun Li's profile →
Citations per field
00.5×3.1×
Xinqun Li · 1×
Citations per year

Countries citing papers authored by Xiaohong Shu

Since Specialization
Citations

This map shows the geographic impact of Xiaohong Shu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaohong Shu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaohong Shu more than expected).

Fields of papers citing papers by Xiaohong Shu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaohong Shu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaohong Shu. The network helps show where Xiaohong Shu may publish in the future.

Co-authorship network of co-authors of Xiaohong Shu

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaohong Shu. A scholar is included among the top collaborators of Xiaohong Shu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaohong Shu. Xiaohong Shu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 5
3 13
4 31
5 21
6 13
7 52
8 12
9 46
10 35
11 57
12 26
13 64
14 21
15 17
16 90
17 46
18 33
19 58
20
[Schistosoma japonicum: protective immunity induced in mice immunized with SjGST-Sj32].
2

About Xiaohong Shu

Xiaohong Shu is a scholar working on Geriatrics and Gerontology, Genetics and Pathology and Forensic Medicine, having authored 63 papers that have together received 1.8k indexed citations. Recurring topics across this work include Sirtuins and Resveratrol in Medicine (12 papers), Cancer Mechanisms and Therapy (8 papers) and Receptor Mechanisms and Signaling (5 papers). The work is most often cited by research in Geriatrics and Gerontology (290 citations), Cancer Research (296 citations) and Molecular Biology (934 citations). Xiaohong Shu has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Chuangang Li, Xiaodong Ma, Kexin Liu, Changyuan Wang, Mo‐Li Wu, Molin Li, Sa Deng, Qing‐You Kong, Xiaohong Chen and Fang Liu. Their work appears in journals such as Angewandte Chemie International Edition, The Journal of Immunology and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026